Background: Computer vision syndrome (CVS), also referred to as digital eye strain, describes a group of eye and vision-related problems that result from prolonged use of a computer, tablet, e-reader, and cell phone. According to Ayurveda, this type of exposure to Tejas (light) along with some unwholesome diet and regimen leads to vitiation of Pitta along with Vata.
INTRODUCTION
The computer has become a part of everyday life at present. In the world, it has been estimated that nearly 60 million people experience vision problems as a result of computer use.
1 According to the US National Institute for Occupational Safety and Health, computer vision syndrome affects about 90% of the people who spend three hours or more a day at a computer. 2 CVS is a group of symptoms which crop up from the extended viewing of the video display terminal (VDT) when the demands of the task exceed the abilities of the viewer. Symptoms comprising CVS are dry and irritated eyes, eye strain/ fatigue, blurred vision, redness in eyes, burning sensation of in the eyes, excessive tear secretion, double vision, headache, light or glare sensitivity, contact lens discomfort, slowness in changing focus, changes in color perception and pain in neck, shoulder and back. These symptoms of CVS are due to ocular (ocular-surface abnormalities or accommodative spasms) and/or extraocular (ergonomic) etiologies. No remedial measures for the prevention or cure of this pathology prevail in the domain of modern medicine except using ocular surface lubricants, computer glasses, and counseling for judicious computer use. 3 On critical review of the pathology of this disease, it seems to be a Vata-Pittaja ocular-cum-systemic disease which needs systemic as well as a topical treatment approach. Acharya Vagbatta has indicated cooling and rejuvenating therapies for eyes affected by bright light, high-voltage electric spark and heat exposure. 4, 5 This phenomenon is also close to the etiopathology of CVS. 
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OBJECTIVES
To assess the clinical efficacy of Mahatriphaladya ghrita and Anu taila nasya in CVS.
MATERIALS AND METHODS
Study Design
The 
Study Participants
A total of 67 participants were screened in accordance with the inclusion and exclusion criteria mentioned in the protocol. Sixty-two patients following the screening criteria were recruited in the study after obtaining the oral and written informed consent.
Inclusion Criteria
• Patients of either sex between 18 years and 35 years of age.
• Patients having minimum three symptoms of CVS (eye strain and fatigue, headache, blurred vision, dry and irritated eyes, neck and shoulder pain, double vision, redness of eyes, burning eyes, excessive tearing, and photophobia).
• Minimum 3 hours daily exposure to any video display terminals (VDTS) like desktop, laptop or both.
• Minimum 1-year exposure to any above mentioned VDTS.
• Willing to participate in the study.
Exclusion Criteria
• Presence of any infectious conditions of the eye, cataract, glaucoma, stye, any fundus pathology.
• Patients having cervical spondylosis or spasm of the trapezius muscle.
• History of any surgical intervention with reference to the eye.
• Patient with history of migraine.
• • History of hypersensitivity to the trial drug or any of its ingredients.
• Pregnant/lactating females.
• Patients who have completed participation in any other clinical trial during the past 6 months.
• Any other condition which the Investigator thinks may jeopardize the study.
Withdrawal Criteria
A subject was to be withdrawn from the study before the expected completion in the following conditions viz. failure to adhere to protocol requirements, subject consent withdrawal, and disease progression. Every subject was free to withdraw from the trial at any time for any reason and without prejudice, or may withdraw on the advice of the investigator. The participants were supposed to be withdrawn from the study in the following circumstances:
• The necessity for taking medications or drugs which according to the exclusion criteria are not permitted during the trial, regardless of whether the need for these has arisen due to the occurrence of complication (including current medical problems) or for other reasons.
• Personal circumstances which cause the subject not to intake the study medication.
• Any subject who withdrawn from the trial was undergone a complete final examination, or if left against medical advice (LAMA) was at least undergone a final telephone interview at the time, with regard to the state of the subject's health, and if necessary, also from the point of view of drug safety and the validity of study results.
• If the patient discontinues the trial drugs more than 7 days at a time was discontinued from the trial.
• The reasons for the withdrawal were recorded in the subject's case record.
Study Interventions
In the preparatory phase, Hingwashtak churna was given in a dose of 3-5 g before meals twice a day for 3 days followed by Virechana with Avipattikar churna 5 g once at bedtime with lukewarm water. Nasya with Anu taila was given in a dose of 8-8 drops in the morning for 7 days (days 1-7). Akshi tarpana with Mahatriphaladya ghrita was done for three consecutive days in the morning and repeated at an interval of 15 days. (i.e., days 8-10 and 26-28 )
Mahatriphaladya ghrita was also given orally in a dose of 5 mL twice a day on empty stomach in the morning and 3 hours before taking meals in the evening with lukewarm water for a total of 42 days starting from day 1.
Procedure of Tarpana
Mild sedation with lukewarm water was given as Purvakarma (preparatory procedure). The concentric boundary needs to be made around each orbit with a paste of Masha churna (powder of Phaseolus mungo L.) and 20-25 mL of lukewarm. Mahatriphaladya ghrita is filled and allowed to remain in the boundary for twenty minutes. Thereafter, Ghrita was removed followed by removal of the boundary. The eye was closed with Akshi bandhana (eye bandage) for 15 minutes.
Procurement of Drug
Trial drugs were procured from GMP certified companyIndian Medicine Pharmaceutical Corporation Limited (IMPCL), Mohan, district-Almora, Uttaranchal-244715.
Outcome Measures
Reduction in signs and symptoms of CVS assessed by using value added services visual analog scale (VAS).
Study Procedure
On the day of enrolment at baseline, the full detail of history and physical examination of the patients was recorded. Clinical assessment was done at baseline, 8th, 26th and 42nd day. There was also a without medication follow-up after 2 weeks, i.e., day 56.
Laboratory Investigations
Laboratory parameters such as liver function tests (LFT), renal function tests (RFT), complete blood count (CBC), erythrocyte sedimentation rate (ESR), hemoglobin (Hb)%, Fasting blood sugar and lipid profile were done at baseline. All the laboratory investigations were done at the end of the 42nd day also.
STATISTICAL ANALYSIS
The data collected at baseline, mid-treatment and after the treatment on outcome measures was tabulated and analyzed by using appropriate statistical methods. Clinical symptoms, subjective parameters and laboratory parameters subjected to univariate and multivariate analysis using the Statistical Package for Social Sciences (SPSS) 15.0 version with appropriate statistical methods.
OBSERVATION AND RESULTS
Data of total 62 patients was used for statistical analysis. Out of which, maximum patients (40.32%) were in the age group of 25-30 years followed by 38.71% belonging to the age group 19-24. Male patients (70.97%) were more sufferers than females, 61.3% were involved in desk work. Table  1 shows the demographic profile of the patients. About 58.1% patients were of Vataja-Pittaja Sharirik Prakriti. Vital parameters of the patients recorded at baseline are shown in Table 2 . 
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Effect of Treatment on Outcome Measures
Effect of the Treatment on Chief Complaints
Effect of the study medications on chief complaints faced by patients suffering from CVS was assessed by paired t-test. A significant (p <0.001) improvement in chief complaints was observed at all subsequent visits (8th, 26th and 42nd day) and follow up (56th day) compared to baseline. However, the effect of treatment on dry and irritated eyes and excessive tearing was statistically significant at 1% level on the 8th day. Improvement in redness of eyes was insignificant on the 8th day. The effect of the trial medications on chief complaints of CVS is shown in Tables 3 to 5 (Graphs 1 and 2). 
Effect of the treatment on Schirmer's I test
Statistically highly significant effect (p < 0.001) was found in Schirmer's I test on completion of treatment as compared to baseline (Table 6 ). Values are expressed as mean (SD), compared using paired t-test at baseline and 42nd day, p-value of <0.05 has been considered as significant.
Effect of the Treatment on Safety Parameters
The effect of this treatment on various safety parameters such as Liver function tests and renal function tests were assessed on the baseline and at the 42nd-day visit. The values were within normal limits during the entire study period (Graphs 3 to 5). Table 7 shows the effect of the drugs on the safety parameters. No statistically significant (p >0.05) change was also seen in lipid profile level (Table 8 ). Values are expressed as mean (SD), compared using paired t-test at baseline and 42nd day, p value of <0.05 has been considered as significant.
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Graph 5: Effect of the treatment on safety parameters (III) Values are expressed as mean (SD), compared using paired t-test at baseline and 42nd day, a p value of <0.05 has been considered as significant. Anutaila nasya is a common formulation used for Pratimarsha and Marsha nasya. Acharya told that Anutaila nasya will give sound health of sense organs. Nasya Karma removes vitiated Vata from Murdha (head) and gives strength to the supraclavicular organs. It is a Snehana (oleation) Nasya thereby also provides nourishment (lubrication) to supraclavicular organs. Nasya is one among the Panchakarma treatments that are aimed to cure the vitiation of Dosha especially residing in the supra-clavicular part of the body. Anutaila Nasya does the Snehana of all the organs in the head and neck region thus of eyes also. Nasya karma itself is known to improve the eyesight. It acts mainly on Prana Vata that resides in the head. Alochaka Pitta which is mainly vitiated in the pathogenesis due to loss of Snigdha Guna gets corrected because of Snigdhata of Nasya.
DISCUSSION
Vitiation of Vata because of its increased
According to Ayurvedic theories related to human physiology and pathogenesis of the disease, whenever dryness is there in any organ or structure, the fats are useful to attenuate it. Grita has Snigdha and Sheeta properties and is an ideal remedy for Vata-Pitta disorders. It forms a uniform layer over the ocular surface after application which brings soothing of eyes and also provides protection from external environment even after removal. Thus combined effect of all these drugs may produce proper nourishment of eyes surface with oleation.
In the present study, a highly significant effect of the therapy was found in reducing chief complaints of computer vision syndrome. The improvement remained steady at the end of follow up without treatment. This shows the long-term effect of the treatment. The safety parameters show that Ayurvedic formulation has no adverse consequences over liver and kidney functions during the study. The drug was well tolerated by the majority of the patients.
CONCLUSION
Mahatriphaladi ghrita and Anu taila nasya is safe and significantly reduces chief complaints of CVS. The improvement remained steady even after two weeks of completion of treatment. This shows the efficacy and long-term benefits of the treatment.
